Reversal of fulminant hepatic failure using an extracorporeal liver assist device

  title={Reversal of fulminant hepatic failure using an extracorporeal liver assist device},
  author={Norman Leslie Sussman and Maria G. Chong and T Koussayer and Danshe He and Thomas A. Shang and Hartwell H. Whisennand and James H. Kelly},
Liver transplantation is currently the only effective therapy for patients with fulminant hepatic failure. The availability of an artificial liver could bridge these patients through the relatively brief crisis period and allow their own livers to regenerate, providing a more favorable outcome and sparing the trauma and expense of transplant. We have developed a device consisting of a highly differentiated human liver cell line cultured in a hollow fiber cartridge. This device is capable of… 
Review: Artificial liver support systems
In a preliminary clinical study, a porcine hepatocyte‐based liver support system is used to treat patients with acute liver failure as well as Patients with acute exacerbation of chronic liver disease, successfully bridged to a transplant with excellent survival.
Bioartificial liver support.
The authors review the history of extracorporeal liver support for acute liver failure and discuss their experience with a hollow fiber bioartificial liver support system utilizing porcine hepatocytes in the treatment of patients with acute Liver failure.
Extracorporeal Liver Support: Waiting for the Deciding Vote
  • M. Adham
  • Medicine, Biology
    ASAIO journal
  • 2003
Although recent studies clearly demonstrate clinical improvement of patients with the use of recently developed liver support devices, most of reported prospective, controlled, or randomized trials had a small number of patients, and conclusive evidence to support the benefits of extracorporeal liver support is still lacking.
Extracorporeal support and hepatocyte transplantation in acute liver failure and cirrhosis
Three bioartificial devices for liver support have undergone preliminary clinical evaluation in the setting of acute liver failure, with a statistically significant reduction in raised intracerebral pressure and improvements in consciousness level and some biochemical parameters associated with treatment with one of these.
Biological extracorporeal liver assist devices: A minireview
Past experience with biological liver-assist devices is reviewed, the field's present status is examined, and the author's own experience with a hepatocyte-based bioartificial liver is summarized.
Cell-based therapy of acute liver failure: The extracorporeal bioartificial liver
A reliable extracorporeal hybrid bioartificial liver based on alginate bead-entrapped hepatocytes was used successfully for the correction of the Gunn rat genetic defect, which results in lack of bilirubin conjugation.
Liver replacement therapy.
The realization of a support device able to effectively replace liver function in patients with hepatic failure has thus far been an elusive goal. The complexity of liver metabolic, synthetic,
Development and testing of a bioartificial liver.
It appears that, at least for now, whole organ transplantation remains the only method with clinically-proven efficacy for treating severe acute liver failure.


Assessment of an extracorporeal liver assist device in anhepatic dogs.
An anhepatic dog model is used to demonstrate the efficacy of a bioartificial liver assist device capable of replacing the metabolic function of the liver, and might provide hepatic support in patients awaiting transplantation or in fulminant hepatic failure.
An improved model of acetaminophen‐induced fulminant hepatic failure in dogs
An improved model of fulminant hepatic failure in dogs is established, using Buthionine sulfoximine to inactivate glutathione synthesis, and small increments of acetaminophen given intravenously to maintain the plasma level at approximately 200 μg/ml for 20 hr.
Liver transplantation.
  • T. Starzl
  • Medicine
    The Johns Hopkins medical journal
  • 1978
The outlook after transplantation appears to have greatly improved, and a one-year survival rate of 50% is projected, and improvements in intraoperative and postoperative management were made with particular reference to biliary tract drainage and to the use of microvascular techniques.
Hemodiafiltration treatment of deep hepatic coma by protein passing membrane: case report.
Although a large-scale controlled trial is needed, PMMA HDF is believed to be promising as a future artificial liver support, and resulted in complete recovery of deep coma and long-term survival in a patient with severe FHF.
Hybrid bioartificial liver in hepatic failure: preliminary clinical report.
A hybrid bioartificial liver has been developed on the principle of hemodialysis against a suspension of functioning hepatocytes and was used successfully to treat a patient in hepatic failure due to an inoperable bile duct carcinoma that involved the bifurcation of the common duct.
A hybrid bioartificial liver composed of multiplated hepatocyte monolayers.
A new hybrid artificial liver containing hepatocyte monolayers that may be a pilot design for the complete artificial liver was manufactured and evaluated and showed good function when compared with suspended cells.